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Background: Physical activity (PA) has been reported to be reduced in severe chronic obstruc-
tive pulmonary disease (COPD). Studies in moderate COPD are currently scarce. The aim of the
present study was to investigate physical activity in daily life in patients with COPD (nZ 70)
and controls (nZ 30).
Methods: A multi-center controlled study was conducted. PA was assessed using a multisensor
armband device (SenseWear, BodyMedia, Pittsburgh, PA) and is reported as the average
number of steps per day, and the time spent in mild and moderate physical activity.
Results: Patients suffered from mild (nZ 9), moderate (nZ 28), severe (nZ 23) and very
severe (nZ 10) COPD. The time spent in activities with mild (80 69 min vs 160 89 min,
p< 0.0001) and moderate intensity (24 29 min vs 65 70 min; p< 0.0036) was reduced in
patients compared to controls. The number of steps reached 87  34%, 71  32%, 49 34%
and 29 20% of control values in GOLD-stages I to IV respectively. The time spent in activities
at moderate intensity was 53 47%, 41 45%, 31 47% and 22 34% of the values obtained in
controls respectively with increasing GOLD-stage. These differences reached statistical signif-
icance as of GOLD stage II (p< 0.05). No differences were observed among centers.berg, Respiratory Division, Herestraat 49, B3000 Leuven, Belgium.
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1006 T. Troosters et al.Conclusions: Physical activity is reduced early in the disease progression (as of GOLD-stage II).
Reductions in physical activities at moderate intensity seem to precede the reduction in the
amount of physical activities at lower intensity.
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Chronic obstructive pulmonary disease was recently
defined as a preventable and treatable disease of the
airways, with significant systemic consequences.1 Inac-
tivity is believed to be crucial to the development of these
systemic consequences of COPD2 such as skeletal muscle
weakness, osteoporosis and cardiovascular disease.3
Recent data suggest that patients suffering from COPD
with low levels of physical activity have increased risk for
hospital admission and have significantly enhanced
mortality.4 Epidemiological data suggest that this may
directly or indirectly lead to more rapid decline in lung-
function.5 In the latter study, patients with COPD were
followed for 20 years. Being moderately physically active
resulted in a median survival benefit of roughly 7 years
compared to patients with a very sedentary life style.
Given the multiple health benefits of appropriate physical
activity it is important to study levels of physical activity,
particularly in mild to moderate disease. Identifying
modifiable risk factors in early disease stages is particu-
larly attractive as it offers the possibility to provide
interventions with potential long term benefits. Recent
guidelines of the American Heart Association have rein-
forced the importance of physical activity in maintaining
health, including the elderly population and patients with
chronic conditions.6
To date, only single centre studies have shown that
patients with moderate to severe COPD have physical
activity levels well below control subjects. Step or motion
counts were 40 to 60 % lower7e9 and walking time was 55 %
lower10 in patients with moderate to severe COPD
compared to healthy control subjects. Patients on long
term oxygen therapy were particularly inactive.8 To our
knowledge, the only data available so far in mild to
moderate COPD come from a cohort that has been followed
in a single center in Germany.11,12 In these studies reduced
daily physical activity was reported as of GOLD-stage II and
a gradual decline of physical activity per GOLD-stage was
found. A limitation of this study is that control subjects
were all former smokers with symptoms of chronic bron-
chitis who were previously connected to the hospital.
Hence it remains possible that physical activity levels could
be even lower in comparison with a healthy control group
with no prior connection to a hospital. Furthermore, only
one study has so far compared physical activity levels from
different centers and showed that patients from South
America were more physically active than patients from
Central Europe.13 This underlines the need to collect data
in different stages of the disease and in different regions of
the world in order to increase the generalizability of
results.
The aim of the present pilot-study was therefore to
investigate physical activity levels in patients across
different disease stages in three different centers locatedin different regions of the world and compare the levels of
physical activity with healthy, age-matched control
subjects.
Materials and methods
A sample of 70 volunteers with COPD was actively recruited
from three outpatient clinics in Palermo, Italy (nZ 29),
Leuven, Belgium (nZ 20), and Pittsburgh, US (nZ 21) by
personal invitations from the pulmonary physician to
participate in the study. In addition, 30 age-matched
healthy control subjects were recruited in Leuven,
Belgium. None of the volunteers had a previous connection
with the hospital and all were relatives of students at the
Department of Rehabilitation Sciences of the Katholieke
Universiteit Leuven. Control subjects could participate if
they were not involved in competitive sports activities and
if they had normal lung function. In the healthy controls
a clinical examination including a maximal cardiopulmonary
exercise test was conducted to exclude any apparent
chronic diseases or other morbidity. Subjects were
instructed to report any current or past health problems.
Resting ECG and lung function were normal in all control
subjects. The appropriate institutional review boards
approved the study and both patients and healthy controls
gave informed consent.
Patients in the study had a known diagnosis of smoking
related COPD and post bronchodilator FEV1 was used to
classify the patients into the appropriate GOLD stage.14
Subjects could participate in the study if they had no other
significant co-morbid conditions that would preclude the
participants from having potentially normal physical
activity levels (except for COPD in the patients). None of
the participants used walking aids, as these may interfere
with the assessment of physical activity levels with the
activity monitor used in the current study. All patients had
stable COPD without exacerbations in the past three
months. None of the patients was referred for rehabilita-
tion. Patients were distributed over the four GOLD stages.
The characteristics of patients and control subjects are
displayed in Table 1.
Study procedures
During an outpatient visit, spirometry was performed
according to the guidelines of the American Thoracic
Society and the European Respiratory Society.15 The best
FEV1 and FVC of at least three acceptable maneuvers are
reported. Body weight and height were assessed on the first
study visit barefoot while wearing light clothing.
Assessment of physical activity
Subjects were instructed to wear a device able to assess
physical activity (SenseWear Armband, Bodymedia,
Table 1 Group characteristics: age, anthropometry, forced expiratory volume in one second (FEV1 in liters and expressed as
a percentage of the predicted value), and Forced Vital Capacity, expressed in % of the predicted value.
Controls COPD P-value
Age (yrs) 65 7 66 9 0.65
Gender (F/M) 11/19 12/58 0.03
Height (cm) 168 8 169 8 0.58
Weight (kg) 74 12 75 15 0.66
FEV1 (L) 3.00 0.73 1.48 0.66 <0.0001
% Predicted 114 16 54 23 <0.0001
GOLD IeIIeIIIeIV (n) e 9e28e23e10
FVC (% predicted) 125 19 93 22 <0.0001
Physical inactivity in patients with COPD 1007Pittsburgh, PA) continuously (day and night) for six to eight
days. The light weight (80 g) activity monitor is worn on the
back of the upper right arm at the level of the triceps. It
assesses accelerations in two planes using a bi-axial
accelerometer. Furthermore skin temperature, near body
temperature, heat flux, and galvanic skin resistance are
assessed and stored in one minute bins for further analysis.
The use of sensors other than accelerometers and multi-
sensor algorithms based on pattern recognition ensures that
the device is relatively insensitive to motion artifacts such
as driving a car or other artifacts due to external body
movements. Total energy expenditure estimates of the
activity monitor have recently been validated against the
gold-standard of doubly labeled water by St-Onge and
colleagues.16 Further promising results concerning valida-
tion of energy expenditure estimates during selected daily
life activities in comparison with indirect calorimetry in
patients with COPD have been reported recently.17,18 The
device switches on automatically upon skin contact.
Adherence with monitor use can be checked directly upon
data retrieval.
The compliance with wearing the device, the number of
steps, and time spent above pre-defined levels of energy
expenditure were calculated and summarized per available
day of assessment. The data reported, represent the mean
values calculated over all days of assessment. Steps and
time spent in at least moderate intense physical activities
were regarded as co-primary endpoints since these
parameters contain information on both the amount of
daily activity and the intensity at which these activities are
performed. Current guidelines stress the importance of
engaging in activities of at least moderate intensity to
achieve health benefits.6 Times spent in mild and high
intensity physical activity were used as secondary
outcomes.
Mildly active time was defined as the time spent in
activities above an estimated energy expenditure of 2.5
Metabolic Equivalents (METs). This represents activities such
as slow walking and light housework.19 The threshold for
moderate physical activities was either set at 4.5 METs for
people up to the age of 65 years or at 3.6 METs for subjects
aged 65 years and older as proposed byHaskell and Pollock.20
Moderate intensity physical activity includes activities such
as brisk walking and sweeping floors and vacuuming.19 Highly
intense activitywas defined as physical activity performed at
an intensity above 6 METs. This includes activities such as
jogging, shoveling, or carrying heavy loads.19Statistical analysis
Statistical analysis was performed using the SAS statistical
package (v8.1, SAS Institute, Cary, NC, USA). Data are
presented using mean and standard deviation, unless
specified otherwise. Baseline characteristics of patients
and controls were compared using a t-test or a chi-square
test. Linear trends for physical activity were compared in
GOLD stages using ANOVA and Tukey’s multiple comparison
tests. Outcomes were compared between centers using
ANOVA testing with Duncan’s post-hoc testing. Correlation
analysis was done using the Pearson’s correlation coeffi-
cient. In addition, a stepwise multiple regression analysis
was performed to identify independent contributors to
physical activity and steps. Age, anthropometric charac-
teristics and FEV1, expressed as a percentage of the pre-
dicted value, were included in the model as possible
covariates. Comparison of physical activity between
centers was done using the general linear models proce-
dure, adjusting for age, gender, body mass index, and
predicted FEV1. A priori, a p-value of less than 0.05 was
considered to be statistically significant.
Results
Patients and healthy controls were matched in terms of age
and anthropometric characteristics except for gender
distribution (Table 1). Distribution of patients across
different GOLD stages is presented in Table 1. Patients in
Pittsburgh were slightly younger (62 10 years) than those
in Leuven (68 7 in Leuven p< 0.05), and slightly more
overweight (BMI 28 5 kg m2) than those in Palermo (BMI
25 5 kgm2, p< 0.05). No other anthropometric differ-
ences were noted.
Physical activity in COPD compared to control
Study subjects wore the activity monitor for an average of
6.23 0.66 days. Patients had significantly lower physical
activity levels compared to control subjects. The number of
steps per day was 5584 3360 in patients, compared to
9372 3574 in controls (p< 0.0001). In patients, the time
spent in activities of moderate intensity reached 36 45%
of control values (24 29 min/day vs. 65 70 min/day;
pZ 0.004) and the time spent in activities of mild (above
2.5 METs) intensity reached 50 43% of controls
Table 2 Reduction in the number of steps and the time
spent in activities of at least moderate intensity (moderate
PA) in patients with mild (GOLD I) to severe (GOLD IV) COPD.
All data are expressed as a percentage of the healthy
control subjects. The p-value represents the significance
level of the difference in the proportional reduction of
steps vs. time in moderate intense PA for each GOLD-stage.
Steps Time in
moderate PA
P-value
Gold I (% controls) 87 35 53 48 0.0008
Gold II (% controls) 70 32 41 45 0.002
Gold III (% controls) 49 34 31 48 0.06
Gold IV (% controls) 29 19 22 33 0.31
1008 T. Troosters et al.(80 69 min/day vs. 160 89 min/day, p< 0.0001). The
time spent in activities of high intensity (above 6 METs) was
only 34 70% of control subjects (2 5 min/day versus
7 9 min/day; pZ 0.01).
Comparison by GOLD stage
Fig. 1 illustrates the gradual reduction in physical activity
levels across GOLD-stages. ANOVA for linear trends was
significant for the number of steps per day and time spent
at mild intensity (data not shown) and moderate intensity.
As of GOLD stage II all physical activity related outcomes
were statistically significantly reduced compared to
controls. Compared to controls, the number of steps per
day was reduced by 13 34, 29 32, 51 34 and
71 20% in GOLD stages I to IV respectively. The time
spent in activities at moderate intensity was reduced by
47 47, 59 45, 69 47 and 78 34% respectively
with increasing GOLD stage. These differences reached
statistical significance as of GOLD stage II (p< 0.05).
Patients in GOLD stage I and II had disproportionably larger
reductions in time spent in moderate physical activities
than in steps. In GOLD stage 1 for example we find a 13%
reduction in steps in contrast with a 47% reduction in
moderate intense physical activity in comparison with
healthy controls (Table 2). In more severe stages theCtrl GOLD I GOLD II GOLD III GOLD IV
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Figure 1 The number of steps (upper panel) and the time
spent in moderate physical activities (lower) in control
subjects and patients with mild (GOLD I) to very severe (GOLD
IV) COPD. Statistical significance of the ANOVA linear trend is
indicated with *, post-hoc analysis indicated that physical
activity was significantly different from controls as of GOLD-
stage II.decline in steps and time spent in moderate physical
activity became more proportional.
Relation of physical activity with clinical and
demographic parameters
In patients with COPD, a significant positive correlation was
observed between FEV1 (%predicted) and the number of
steps per day (RZ 0.51, p< 0.0001), time spent in activi-
ties of mild intensity (RZ 0.33, pZ 0.006), but not time
spent at moderate intensity (RZ 0.18, pZ 0.14). In addi-
tion a significant inverse relation was found between age
and the number of steps (RZ0.33, pZ 0.006) and time
spent in activities at mild intensity (RZ0.23, pZ 0.05).
In a stepwise multiple regression analysis FEV1 (partial
R2Z 0.26, p< 0.0001) was positively, and age (partial
R2Z 0.11, pZ 0.001) was negatively related to the number
of steps per day (total R2Z 0.37). Similar results were also
noted for mild physical activity in a stepwise multiple
regression analysis with FEV1 (partial R
2Z 0.11,
pZ 0.0058) being a positive predictor, and age (partial
R2Z 0.05, pZ 0.0428) as a negative predictor (total
R2Z 0.16). No significant predictors of time spent in
moderate physical activity were noted.
As expected, the different physical activity estimates
from the armband were related. A correlation was found
between the time at moderate intensity (RZ 0.50,
p< 0.0001), and the number of steps. A better relation was
obtained between the time spent at intensities> 2.5 METs
(mild) and the number of steps (RZ 0.84, p< 0.0001).
These relations are displayed in Fig. 2.
There were no significant differences in disease severity
between centers (FEV1: 59%, 55%, and 50% of the predicted
value in Pittsburgh, Palermo and Leuven respectively).
After correcting for covariates age, BMI, FEV1 and gender,
the mean number of steps were 6383 643 (SEM) in
Leuven, 5115 675 in Pittsburgh and 6610 804 in
Palermo, respectively. The time spent at moderate inten-
sity was found to be 27 7 min in Leuven, 21 7 min in
Pittsburgh, and 10 8 min in Palermo. These estimates for
time in mild physical activity were 93 15 min in Leuven,
62 15 min in Pittsburgh, and 64 18 min in Palermo,
respectively. None of these differences reached statistical
significance. The ‘Center’ did not contribute in the multiple
regression analysis to explain variability in physical activity.
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Figure 2 Relation between the numbers of steps per day and the time spent in mild activities (Left panel) and the time spent in
moderate intensity (Right panel) in patients (open symbols) and control subjects (closed symbols).
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The main finding of this pilot-study is the significant
reduction in physical activity observed at each of three
centers as of GOLD-stage II. The study provides evidence
for a gradual reduction in daily physical activity levels with
increasing GOLD stage, although the correlation between
physical activity and lung function is weak. Our data clearly
show that inactivity starts early in the disease and this
pattern was consistent across centers.
The present study was partly designed to investigate the
feasibility of physical activity monitoring in larger multi-
center trials. There are three noteworthy findings to be
highlighted. First, the present study shows that is feasible
to use activity monitors in multi-center studies. Patients
showed good compliance wearing the activity monitor. For
93% of the days, the activity monitor was worn for more
than 90% of the time. To our knowledge only one other
study so far reported data on compliance and found that
a tri-axial accelerometer was only worn for 60e70% of the
instructed time (daytime hours).21 Whether these differ-
ences in adherence are caused by the measuring devices
themselves or due to the instructions given to the patients
needs to be further explored. Furthermore no large
differences between centers were found for intensity and
amount of daily activity. This is in contrast with recent data
showing significantly different levels of physical activity in
patients from Austria in comparison with patients from
Brazil.13 Further studies in larger samples are needed to
clarify whether systematic differences in physical activity
levels exist between countries. The current conclusions are
based on relatively small samples and could be influenced
by selection bias.
Second, in the present study physical activity level was
assessed using steps; an outcome which is conventionally
assessed using pedometers or accelerometers. In addition,
the time spent above pre-determined thresholds of inten-
sity was calculated. We used an age dependent threshold to
identify physical activity at moderate intensity and activi-
ties above 2.5 METs were classified as mild physical activity.
In patients with moderate disease physical activity at
moderate intensity was clearly more reduced (60%) than
the number of steps (29%, Table 2). Time at moderate
physical activity is important to maintain or improve
physical fitness and health.22 Simply using steps as anoutcome may therefore overestimate the level of physical
activity probably because the walking speed of patients is
rather low. Hence, despite what current knowledge might
consider to be a reasonable step count24 (or pedometer
count), patients may still fail to reach the recently updated
recommendations to maintain health (i.e. more than
30 minutes of physical activity at moderate intensity on 5
out of 7 days).22
Lastly our study reinforces the importance of physical
activity monitoring, rather than the use of questionnaires
to accurately assess physical activity. In a large population
based study conducted in Denmark, the proportion of
patients with low physical activity levels in GOLD-stage I
was 11%.4 In the whole cohort this proportion was 13%.5 In
GOLD-stage II the proportion of inactive patients was 21%.
Our data and that of others11 suggest more important levels
of inactivity in these milder stages in comparison with
healthy controls which is probably related to the method of
measuring.23
Although the present study is one of the largest studies
to investigate physical activity levels in patients across
different stages of COPD and in healthy controls, a word of
caution is needed when interpreting the data. Since healthy
controls were only recruited from one Belgian centre it is
possible that they are not completely representative for
the general level of activity in this age cohort. Activity
questionnaire data from large population samples suggest
that Belgians are among the least active populations
worldwide.25,26 Furthermore there was a slightly larger
proportion of females in the control cohort. Both of these
facts have probably resulted in a rather conservative esti-
mate of normal activity in our study and may therefore
have resulted in an underestimation of the difference
between patients and controls.
We studied a substantially larger group of patients in
GOLD-stage II compared to previous studies, which largely
focused on GOLD-stages III and IV.7e10 Our data show
remarkable similarity with two other recent studies that
used similar methodology to assess physical activity
levels.11,12 The number of steps in their patients in
GOLD-stage I was 7990 3370 (vs. 8141 in the present
study). Pooling the results from both studies, patients in
GOLD-stage I tended to be less active compared to the
control subjects of the present study (pZ 0.12). Steps of
control subjects were also very similar (9110 3857 vs.
1010 T. Troosters et al.9372 3574 in the present study). The reduction of physical
activity levels at moderate intensity by up to 40 to 50% in
patients suffering from moderate COPD clearly emphasizes
that treatment in these patients should include attention to
enhance physical activity levels.
Although pulmonary rehabilitation should aim at
enhancing physical activity2 surprisingly few studies have
investigated the impact of pulmonary rehabilitation on
physical activity in general. None of these were specifically
directed at patients in GOLD-stage II. Some uncontrolled
studies have on average shown modest improvements of
physical activity levels after exercise training.25e32 One of
these studies suggests that pulmonary rehabilitation is
particularly effective to increase participation in daily
physical activity in patients in early disease stages.29 The
effect of drug therapy on physical activity levels is not
studied. Several bronchodilators have been shown to
enhance exercise tolerance.33e35 Whether this translates
into more participation in daily physical activity is currently
under investigation.
In COPD, pilot data suggest that physical activity levels
could be enhanced by increasing awareness on the actual
physical activity levels by using a simple pedometer.36 This
strategy seems to be effective across different patient
populations and also in healthy sedentary adults.37
Previous studies suggested that the association between
physical activity and lung function was weak10,38 to
moderate.39 In the present study the positive relation with
the total number of steps (RZ 0.51, p< 0.0001) and physical
activity at mild intensity (RZ 0.33, pZ 0.006) are statisti-
cally significant. The relation with physical activity at
moderate intensity, however, is not significant. In fact the
reduction in moderate physical activity is large, even in mild
disease. It is important to mention that these activities at
moderate intensity are required tomaintainoptimalhealth.22
In conclusion, the present multi-center study confirms
the impressive reduction in physical activity in a relatively
large group of patients with moderate COPD (GOLD II) as
well as those with more severe disease (GOLD Stage III & IV)
across different centers in different countries. Further
research should focus on interventions focused specifically
on enhancing physical activity in these patients.
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